US buys 30,000 courses of intravenous antivirals for H1N1 - updated
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals has shipped 10,000 treatment courses of its intravenous antiviral peramivir to the US health and human services (HHS) department under a $22.5 million contract aimed at countering the toll of H1N1 influenza. The order came less than two weeks after the FDA authorised peramivir, an unapproved drug, for emergency use in hospitalised H1N1 patients (scripnews.com, October 26th, 2009).